BioXcel Therapeutics, Inc. BioXcel Therapeutics, Inc.

  • About
    • Overview
    • Management Team
    • Board of Directors
    • Strategic Advisors
  • Product Pipeline
    • Overview
    • Expanded Access
  • News & Media
    • Press Releases
    • Publications
    • Events
    • Media
  • Investors
    • Investor Relations
    • Overview
    • News / Events
    • Overview
    • Press Releases
    • Press Coverage
    • IR Calendar
    • Email Alerts
    • Company Info
    • Overview
    • Presentations
    • Management Team
    • Contacts
    • FAQ
    • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
    • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Business Development
  • Careers
    • Overview
    • Job Openings
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Press Coverage
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • IR Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • Press Coverage
  • IR Calendar
  • Email Alerts

BioXcel Therapeutics Receives FDA Orphan Drug Designation for BXCL701 for the Treatment of Acute Myeloid Leukemia (AML)

Sep 4, 2019

BioXcel Therapeutics Announces Award of Grant by U.S. Department of Defense’s (“DoD”) Congressionally Directed Medical Research Programs (“CDMRP”) for Development of BXCL501

Aug 20, 2019

BioXcel Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update

Aug 6, 2019

BioXcel Therapeutics to Present at the Canaccord Genuity 2019 Annual Growth Conference

Jul 31, 2019

BioXcel Therapeutics to Report Second Quarter and Half Year 2019 Financial Results and Business Update

Jul 30, 2019

BioXcel Therapeutics Announces BXCL501 Met Primary Endpoint in Phase 1b Placebo-Controlled Trial in the Treatment of Agitation in Patients with Schizophrenia

Jul 22, 2019

BioXcel Therapeutics Added to Russell 3000® Index

Jul 1, 2019

BioXcel Therapeutics to Participate in the BMO 2019 Prescriptions for Success Healthcare Conference

Jun 18, 2019

BioXcel Therapeutics Completes Dosing Two Cohorts of Agitated Schizophrenia Patients with BXCL501 in a Phase 2 Efficacy Trial

Jun 10, 2019

BioXcel Therapeutics CEO, Dr. Vimal Mehta to Participate in BIO International Convention Panel on Innovative Clinical Trial Designs

Jun 6, 2019
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...15
    © 2021 BioXcel Therapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap